NCT02352506

Brief Summary

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

January 28, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 2, 2015

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2019

Completed
3.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

March 15, 2023

Status Verified

March 1, 2023

Enrollment Period

4.8 years

First QC Date

January 28, 2015

Last Update Submit

March 13, 2023

Conditions

Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

  • Macrophage migration inhibitory factor

    Up to 14 days

Secondary Outcomes (1)

  • Serum creatinine

    Up to 14 days

Study Arms (2)

AKI

Patients developing AKI during the ICU stay

Other: Blood draw for measurement of MIF

No AKI

Matched controls not developing AKI during the ICU stay

Other: Blood draw for measurement of MIF

Interventions

Blood draw for measurement of MIFOTHER

Observational study, no intervention

AKINo AKI

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Critical care patients

You may not qualify if:

  • Age \< 18 years and \> 80 years
  • Patients with chronic dialysis
  • Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
  • Patients with an expected length of ICU stay shorter than 3 days
  • Patients with a low probability of surviving the first 2 days after ICU admission
  • Pregnancy and nursing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Acute Kidney Injury

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Univ.-Ass.

Study Record Dates

First Submitted

January 28, 2015

First Posted

February 2, 2015

Study Start

January 1, 2015

Primary Completion

November 1, 2019

Study Completion

January 1, 2023

Last Updated

March 15, 2023

Record last verified: 2023-03

Locations

AU(1)